《大行報告》美銀證券上調名創優品(09896.HK)目標價至46.6元 評級「買入」
美銀證券發表報告指,名創優品(09896.HK)在過去四個季度顯示出強勁的利潤率復甦,淨利潤率亦超出2019年水平,即使每店銷售仍較2019年水平低出介乎20%至40%。該行預料,利潤率於2024財年持續擴張,營運槓桿有望擴張,以及營收加速增長。
該行認為,即將公布的6月底止季度業績或是近期催化劑,料收入按年升35%至32億元人民幣,淨利潤率料達16.9%。該行表示,將公司在2023年至2025年每股盈測上調介乎5%至11%,並將其H股目標價由41.9元上調至46.6元,維持其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.